Abstract
Hormonal contraceptives (HCs) are widely used for birth control and management of various gynecological conditions However, their systemic effects particularly on inflammatory markers and thrombotic risk, remain a subject of ongoing investigation where in This study aimed to examine the impact of hormonal contraceptive use on systemic inflammation and thrombotic risk factors in women over a 12-month period in addition to Methods of study refer to An observational cohort study was conducted from March 2024 to March 2025 across multiple hospitals in Iraq with Eighty women of reproductive age were enrolled and divided into two groups: HC users and non-users and Data collected included demographic information, laboratory results (blood glucose, cholesterol, CRP, IL-6), hormonal profiles, thrombotic risk factors, and patient-reported outcomes. Laboratory assessments were performed at baseline and after 12 months. where In this paper Statistical analysis involved descriptive statistics, independent t-tests for group comparisons, and correlation coefficients to assess relationships between inflammatory markers and thrombotic risk. The results in this study refer to HC users demonstrated significantly higher levels of inflammatory markers (CRP, IL-6) and altered coagulation profiles compared to non-users (p < 0.05) and Correlation analysis revealed a positive association between duration of HC use and increased thrombotic risk factors Despite these findings, some users reported improved quality of life and satisfaction with contraceptive methods finally we concloude Hormonal contraceptive use is associated with elevated systemic inflammation and increased thrombotic risk in women, highlighting the need for individualized risk assessment and patient education.